S
Seito Biologics develops selective T‑reg cell engager (TREX) cytokine therapies that boost regulatory T‑cell function and numbers. By restoring T‑reg activity, its treatments aim to rebalance immune responses in autoimmune and inflammatory diseases. The platform leverages IL‑2‑based engineering to provide targeted immunomodulation with a focus on safety and efficacy.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Seito Biologics develops selective T‑reg cell engagers (TREX) that enhance regulatory T‑cell function to restore immune balance. Its cytokine‑based therapies target autoimmune and inflammatory diseases by increasing T‑reg numbers and activity. The platform leverages IL‑2 engineering to deliver targeted immunomodulation with a focus on safety and efficacy.